Overview

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Status:
Recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Carboplatin
Pemetrexed